The American Heart Association (AHA), in collaboration with other medical societies, has released updated guidelines for the management of blood cholesterol. The new recommendations, published in the journal Circulation, emphasize a more personalized approach to assessing an individual's risk for atherosclerotic cardiovascular disease (ASCVD). This shift aims to better identify patients who would benefit most from cholesterol-lowering therapies.
A key update involves the use of coronary artery calcium (CAC) scoring to guide treatment decisions, particularly for patients at intermediate risk. The guidelines also provide updated recommendations on the use of statins, ezetimibe, and newer PCSK9 inhibitors, tailoring the intensity of therapy to the patient's specific risk profile and response to initial treatment.
Dyslipidemia, including high cholesterol, remains a major modifiable risk factor for heart disease and stroke. The AHA stresses that these evidence-based updates are designed to help clinicians and patients make more informed decisions to prevent cardiovascular events through lifestyle changes and, when necessary, appropriate medication.
